In Sub-Saharan Africans, maternal mortality is unacceptably high with >400 deaths/100,000 births compared to <10/100,000 in Europeans. One third of the deaths are caused by pre-eclampsia, a syndrome arising from defective placentation. Controlling placentation are maternal natural killer cells that use killer-cell immunoglobulin-like receptors (KIR) to recognize the fetal HLA-C molecules on invading trophoblast. We analysed genetic polymorphisms of maternal KIR and fetal HLA-C for 484 normal and 254 preeclamptic pregnancies at Mulago Hospital, Kampala, Uganda. The combination of maternal KIR AA and fetal HLA-C2 associates with pre-eclampsia (P=0.0318, OR 1.49). The KIR genes associated with protection are located in centromeric KIR B regions that are unique to Sub-Saharan African populations and contain the KIR2DS5 and KIR2DL1 genes (P=0.0095, OR 0.59). By contrast, telomeric KIR B genes protect Europeans against pre-eclampsia. Thus, different KIR B regions protect Sub-Saharan Africans and Europeans from pre-eclampsia, whereas in both populations the KIR AA genotype is a risk factor for the syndrome. These results emphasize the importance of undertaking genetic studies of pregnancy disorders in African populations with the potential to provide biological insights not available from studies restricted to European populations.
Introduction
Although pre-eclampsia presents clinically with a diverse array of systemic symptoms, the underlying disease-causing mechanism starts with placentation when trophoblast cells invade the decidua. Here they transform the uterine spiral arteries into large vessels that form the feto-placental supply line (1, 2) . In preeclampsia and other pregnancy disorders (fetal growth restriction (FGR), stillbirth, recurrent miscarriage), known collectively as the Great Obstetric Syndromes (GOS), trophoblast fails to invade optimally (3) . Pre-eclampsia and other GOS occur in all populations but women of African ancestry are significantly more at risk and thus GOS are responsible for much of the high maternal and fetal mortality rates seen in Sub-Saharan Africa (SSA) (4) . The genetic contribution to pre-eclampsia is supported by several studies and involves both maternal genes and the paternal genes inherited by the fetus (5, 6) .
The wall of the uterus is the territorial boundary between two genetically different individuals: the mother and the fetus. The uterine mucosal immune system appears to define this maternal/placental boundary. The decidua must control placentation, because in its absence the trophoblast infiltrates to a dangerous extent, causing the condition of placenta percreta (7) . The decidua contains an abundant population of specialized NK cells. These uterine NK cells (uNK) express Killercell Immunoglobulin-like Receptors (KIR) that recognize trophoblast HLA-C ligands (8, 9) . Both KIR and HLA-C are genetically variable, resulting in many possible combinations of maternal KIR and fetal HLA-C ligands (10) . The KIR region is defined by two groups of haplotype: A and B. The KIR A haplotype has seven KIR genes, all encoding inhibitory receptors apart from KIR2DS4. In contrast, the KIR B haplotype contains a variable number of additional KIR most of which encode activating receptors (11, 12) . All HLA-C allotypes are KIR ligands and can be divided into two groups, carrying either C1 or C2 epitopes, that are distinguished by a dimorphism at position 80 and are recognized by different KIR (13) . Within a human population the combination of KIR and HLA diversity distinguishes individuals. Worldwide human populations exhibit considerable differences and this is particularly true for Sub-Saharan African populations. They exhibit less linkage disequilibrium between the KIR genes Submission PDF Fig. 1 . Frequency of the KIR AA genotype alone and in combination with the fetal HLA-C carrier group in Uganda and in the UK.There was a significant difference in the KIR AA genotype frequencies between controls (grey bar) and pre-eclampsia cases (black bar) in both the Ugandan, *P=0.0256, OR 1.45, and the UK cohorts, ***P=0.0005, OR 1.51. The frequency of KIR AA genotypes is shown when combined either with a fetus carrying a C2 epitope or those lacking C2 and carrying only C1-bearing HLA-Callotypes. There is a significant risk of pre-eclampsia when a KIR AA women has a fetus carrying a C2 epitope for both cohorts; in Uganda *P=0.0318, OR 1.49, in the UK *P=0.0267, OR 1.46.
than other populations (14) (15) (16) , and the KIR genes have greater allelic diversity (15, 16) . A variety of diseases and clinical conditions have been associated with combinations of HLA-C and KIR genes. In previous case-control studies of pre-eclampsia in pregnant European women we showed that when the fetus carries a C2 epitope, maternal KIR AA genotypes are risk factors for pre-eclampsia, whereas the KIR2DS1 gene of maternal KIR B haplotypes is protective (8, 17) . In the case-control study reported here we test the hypothesis that these factors confer similar risk and protection to pregnant Sub-Saharan African women.
Results

Clinical characteristics of the cohort.
This case-control study of pre-eclampsia involved 738 pregnant women at Mulago Hospital, Kampala in Uganda. More than 90% of cases and controls were Bantu, the largest ethnic group, with small numbers of Luo, Nilo-Hamites and other ethnic groups. The ethnicity of the male partners and the sex ratios of the singleton babies in all the groups were similar (Table S1 ). HIV+ women were not excluded from the analysis as there were similar numbers in both pre-eclamptic and control pregnancies (∼5%) (Table S1 ) and similar results were found even when HIV+ women were omitted (Table S2) . As expected, the gestational age at delivery and the birth weights were significantly lower in the pre-eclamptic cases compared to controls (P<0.001, Table S1, Figure S1 ).
Unlike European women, KIR B centromeric regions containing KIR2DS5 protect Ugandan women from pre-eclampsia. (Figure 2A ) (Table 3) . In comparable studies on European women, protection was seen with KIR2DS1 and not with KIR2DS5 as shown here for African women (Table 1) . Moreover, in the Ugandans, the telomeric B (tB) genes KIR2DS1 and KIR3DS1 are at similar low frequency in cases and controls ( Table 1) .
As KIR genes are in linkage disequilibrium, KIR2DS5 could be itself protective or marking a nearby protective gene. KIR2DS5 can be found in both the KIR centromeric B (cB) and telomeric B (tB) regions. To determine the location of KIR2DS5 in our cohort, we grouped individual genotypes according to their combination of centromeric and telomeric KIR regions, based on previously described African KIR haplotypes (see Methods and Figure 3 ). Genotypes characteristic of expanded or contracted regions were also identified and shown to have similar frequencies in cases and controls.
Next, allele-level KIR2DS5 typing was performed, which identified ten alleles that were assigned to cB or tB regions as described in Methods (Figure 4 ). KIR2DS5*004, *006, *007, and *010 are restricted to cB, whilst KIR2S5*002, *003, *008, *009 and *011 are restricted to tB. KIR2DS5*005 is the most frequent allele and the only one found in both cB and tB (Figure 4 ), pointing to it being the progenitor of all other KIR2DS5 alleles. Our assignments of KIR2DS5 alleles to cB or tB agree with those defined by complete KIR haplotype sequences and analysis of African and African-American families (15, 18, 19) . With all this information, we were able to determine the centromeric or telomeric location of KIR2DS5 for all KIR2DS5-carrying individuals.
Comparison of the frequency of the centromeric and telomeric KIR2DS5 alleles in cases and controls shows that they differ in the protection they provide against pre-eclampsia. KIR2DS5 is protective in Ugandan women when it is present in the cB region (cB01 or cB03, P=0.0095, OR 0.59) ( Figure 2B , Figure  3 , Table S3 ). Furthermore, of all the cB KIR2DS5 alleles, only KIR2DS5*006 is significantly more frequent in controls than in pre-eclamptic pregnancies (P=0.0015, OR 0.35) ( Figure 2C , Table S4). The dominant allele, KIR2DS5*005, has similar frequencies in both cases and controls even when we can unequivocally assign its location to cB and thus appears neutral. Consistent with the low frequency of KIR2DS1 and KIR3DS1 in Africans, KIR2DS5 is less frequently present in tB than cB. When present in tB it has no effect, being at similar frequencies in controls and cases ( Figure 2B , Table S3 ). Thus, the protective effect of KIR B is not just the absence of KIR A genes but also the presence of genes belonging to a particular subgroup of cB regions, cB01 or cB03 ( Figure 3) .
In Ugandan women, like European women, pre-eclampsia associates with maternal KIR AA genotype combined with fetal expression of paternal HLA-C2. We further examined the effect of different combinations of maternal KIR and fetal ligands, C1 and C2 epitopes of HLA-C allotypes. Considered alone, the C1 and C2 frequencies in mothers and babies do not significantly differ between cases and controls (Table S5) . Using an extended Mantel-Haenszel test for linear trend, we find that KIR AB or BB genotype mothers carrying a C1C1 homozygous fetus have the least risk of pre-eclampsia, whereas a KIR AA mother carrying a C2 fetus has greatest risk (P=0.0122) ( Figure S2 , Table S6 ). Other genetic combinations have risks between these two extremes.
If the fetus has one more HLA-C allele encoding a C2 epitope than the mother, then the fetus must have inherited this C2 from the father. In this situation, the risk of pre-eclampsia in the absence of KIR2DS5 is increased (P=0.0130, OR 1.72) ( Table  2) . To explore this further we defined the parental origin of the C2 for C1C2 heterozygous fetuses. When the single C2 is paternally inherited the risk of pre-eclampsia associated with the absence of KIR2DS5 is greater (P=0.0203, OR 1.80) than when it is maternally inherited (NS, OR 1.16 CI 0.72-1.84) ( Table 2) . Taken together, these findings show that there is an increased risk of pre-eclampsia in women with a KIR AA genotype lacking Submission PDF 
Fig. 4.
Carrier frequencies of the different KIR2DS5 alleles found in the Ugandan population. cB alleles are in shades of red, tB alleles shades of blue, KIR2DS5*005 (purple) is found in both cB and tB.
KIR2DS5 when the fetus has a HLA-C allele encoding a C2 epitope inherited from its father.
Recurrence of pre-eclampsia in Ugandan women is associated with maternal KIR AA genotype and fetal expression of paternal C2. The risk of recurrence of pre-eclampsia is known to be high (∼20%) (20, 21) . In our cohort were 24 pre-eclamptic women who had recurrence of a hypertensive disorder of pregnancy, a condition on the same spectrum as pre-eclampsia. The 45.8% frequency of the KIR AA genotype in these women with recurrent pre-eclampsia was even higher than the frequencies of 36.3% in the full cohort and 28.2% in controls. Ten of the eleven KIR AA pregnancies in this sub-cohort carried a C2 fetus.
Discussion
Our genetic study in an African population not only supports previous findings that certain combinations of maternal KIR and fetal HLA-C variants are associated with pre-eclampsia but also reveals the benefits of studying multiple populations including those most at risk of a disease. Pre-eclampsia occurs more commonly in African women and the symptoms are of severe, early onset disease associated with low birth weight and high mortality (4). Our findings have relevance to other disorders of pregnancy as unexplained stillbirth, fetal growth restriction and preterm labour are more common women with African ancestry and share the same underlying problem of defective placentation with reduced maternal blood flow to the placenta (4).
There is considerably more genetic diversity of KIR genes in Africans both at the level of KIR haplotypes and number of alleles at individual KIR loci (10, 15, 16) . Despite this complexity, we find complete consistency with our studies of pre-eclampsia in Europeans: the risk is associated with a maternal KIR AA genotype combined with a paternally-derived HLA-C allotype carrying a C2 epitope in the fetus (8, 17) . Recurrent pre-eclampsia frequently occurs in African women (24.6% in a recent Tanzanian study) and the high frequency of KIR AA genotypes in these women in our study is striking (45.8% compared to 28.2% in controls) (21) . The KIR always present on the KIR A haplotype likely to confer this risk for is KIR2DL1, an inhibitory KIR with strict specificity for C2 epitopes (22) . Thus, in women with a KIR AA genotype containing two copies of KIR2DL1, uNK will be strongly inhibited when confronted by HLA-C2+ trophoblast. There are at least 12 KIR2DL1 alleles located in cA region in Africans compared to 1-5 in other populations (15) . In the future analysis of larger cohorts, including more women with recurrent pre-eclampsia, should identify if there are particular KIR2DL1 alleles responsible.
One clear difference that might partially explain the increased risk of pre-eclampsia in Africans is the higher frequency of C2-bearing HLA-C allotypes across SSA compared with elsewhere in the world (14) . The probability of African women having a C2-positive partner or fetus is 80% compared to 64% for European women. Similarly the probability of African women having a fetus carrying a paternal C2 epitope is 55%, compared to 40% for European women (Table S4) . Given the selective pressure that pre-eclampsia imposes on a population, there must be other scenarios where C2 epitopes are beneficial. HLA-C and KIR are immune system genes with roles in outcome from viral infections such as HCV and HIV (10, (23) (24) (25) . In SSA C2 epitopes might be advantageous in responding to a range of pathogens, including malaria. Studies of how HLA-C and KIR variants affect responses to infection in SSA are still limited, especially in the crucial period from birth to adolescence.
We observed that tB regions containing KIR2DS1 provide a protective effect for pre-eclampsia in Europeans (8). In contrast, we now show that in Ugandans KIR cB regions characterized by KIR2DS5, KIR2DP1 and KIR2DL1 (cB01 and cB03) are protective. The low carrier frequency of KIR2DS1 in SSA (1.4%-27.8%) compared to Europe (42.5%) also suggests that KIR2DS1 does not play an important role in pregnancy success in Africans (14) . One explanation for the different protective effect is that KIR2DS5, an activating KIR that likely evolved from a KIR specific for C2, does function like KIR2DS1 -although there is no evidence to date that the C2 epitope is a KIR2DS5 ligand (22) . The single KIR2DS5 allele in Europeans, KIR2DS5*002, is in tight LD with KIR2DS1 and located in the tB region. Unlike Europeans though, KIR2DS5 is polymorphic in Africans and African-Americans. We found 10 alleles in Ugandans, consistent with previous reports from African Americans 409  410  411  412  413  414  415  416  417  418  419  420  421  422  423  424  425  426  427  428  429  430  431  432  433  434  435  436  437  438  439  440  441  442  443  444  445  446  447  448  449  450  451  452  453  454  455  456  457  458  459  460  461  462  463  464  465  466  467  468  469  470  471  472  473  474  475  476   4 www.pnas.org ------Footline Author   477  478  479  480  481  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502  503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540  541  542  543  544 Submission PDF (IPD), located in both cB and tB, but most commonly found in those cB regions that also contain KIR2DP1 and KIR2DL1 (26, 27) . The dominant allele, KIR2DS5*005 is the only allele found in both cB and tB and is probably ancestral; when in either location it was similar in frequency between cases and controls. Of the cB KIR2DS5 alleles, only KIR2DS5*006 is significantly associated with protection from pre-eclampsia. KIR2DS5 can be expressed by European pbNK but we have been unable to demonstrate its expression on uNK using similar reagents (28) (29) (30) . The functional effects of KIR2DS5 diversity await further investigation but certain KIR2DS5 allotypes do show different expression levels in transfected cells, similar to findings for other KIR variants (30) . For example, allelic variation of KIR2DL1 affects expression levels at the cell surface, NK repertoire and affinity of binding (22, 31, 32) . Furthermore, although no binding has been demonstrated of the European allele, KIR2DS5*002, to any HLA ligand, KIR2DS5*006 might bind to C2 epitopes common in Africans (C*04, C*02, C*17, C*18)(15). Another possibility is that KIR2DS5 is in LD with other KIR on the protective cB01 and cB03 regions, notably KIR2DL1. The cB KIR2DL1 allele present in Europeans, KIR2DL1*004, gives a weak inhibitory signal compared to the common cA allele, KIR2DL1*003 (31) . Thus, the protective effect of the cB01 and cB03 regions could either be due to KIR2DS5 activation or weaker KIR2DL1 inhibition, as both might counter-balance the strong inhibition conferred from cA KIR2DL1 alleles. For both KIR A and B haplotypes, the particular KIR2DS5 and KIR2DL1 alleles involved are therefore important, but to investigate this will require much larger, clinically well-characterised cohorts. Our method to infer KIR regions allows a fairly simple analysis of KIR data from clinical cohorts in SSA compared to the complex sequencing needed to define the exact haplotypes (15) . Hence, although this analysis does not unravel the complete complexity of KIR variants found, it can point to the regions conferring risk or protection. In this clinical context we have a clear pointer that the cB01 and cB03 regions, containing KIR2DS5, KIR2DL1 and KIR2DP1, are providing protection from pre-eclampsia in Ugandan women.
In this African cohort, as in Europeans, a paternal rather than maternal origin of fetal C2 confers risk in women lacking KIR2DS5 (8) . Whether this effect is due to disparities between individual maternal and paternal HLA-C2 allotypes (allogeneic) and/or a dosage effect (more HLA-C alleles encoding C2 in the fetus than in the mother when C2 is paternally derived) is unresolved (8) . This will require high-resolution genotyping of C1C2 mothers who have C1C2 babies (where the dosage is identical) in a large cohort (2000 cases and 4000 controls would be required).
The great diversity of KIR and HLA-C variants in SSA is maintained by balancing selection (10) . The two contrasting functions of these immune system gene families in reproduction and immune responses to infection mean certain variants will be important at different stages of life in women, men, children and adults and in geographical regions with a range of different pathogens. We have previously argued that the selective pressures from reproductive success and immune response to pathogens are competing and have driven evolution of the KIR A and B haplotypes in humans compared to other hominids (10) . Our combined studies of KIR/HLA-C variants in diverse European and African populations now suggest that the unusual reproductive strategies characteristic of modern humans compared to other hominids could also be a cause of balancing selection. The evolution of the large neonatal brain relative to a pelvis adapted for bipedalism means birth weight must be kept between two strictly defined limits. When babies are large (>95 th centile) there is a risk of cephalo-pelvic disproportion and subsequent prolonged obstructed labour, birth asphyxia and post partum haemorrhage. Furthermore, these outcomes are also much more common in African women with associated features of pregnancy that favour smaller babies: earlier birth -the gestational age is reduced to 38 weeks, the head engages late into the pelvis and the baby matures earlier than in non-Africans (4). Thus, there is not only high mortality in mother and babies from pre-eclampsia (associated with low birth weight and still birth), but also at the other end of the normal birth weight spectrum. Both mothers and their babies benefit if the latter have intermediate birth weights and the two extremes of very low and high birth weight are selected against. The balance between these two extremes is partially determined at placentation when uNK allow trophoblast cells to access sufficient maternal oxygen and nutrients without starving the baby (defective trophoblast invasion) or risking uterine rupture (excessive trophoblast invasion) (3) . In an African population, because of the greater risk of cephalo-pelvic disproportion (4), there is even greater selection for reduced fetal size with associated pre-eclampsia -this is consistent with the higher frequency of maternal KIR AA/paternal C2 combinations in SSA.
In Europeans, opposing KIR/HLA-C combinations are associated with the extremes of birth weight: a paternal C2 epitope is associated with both extremes, but in pre-eclampsia and low birth weight (<5 th centile) the risk is with maternal KIR AA genotypes, whilst in high birth weight the association is with maternal KIR2DS1 (33) . Studies on how these genetic findings are translated in uNK functional differences are still limited but we found that when KIR2DS1+ uNK (isolated from UK patients) are activated by target cells expressing HLA-C2, there is increased production of soluble factors (eg GM-CSF) that enhance trophoblast invasion (34) .
Thus, there is a balance between the KIR A and KIR B haplotypes in both populations but they differ in the regions of the KIR B haplotype that correlate with protection from preeclampsia. tB regions and KIR2DS1 are infrequent in Africans compared to Europeans but the opposite is true for cB regions containing KIR2DS5. During the out-of Africa migrations it is possible that only individuals with tB with KIR2DS1 moved away from SSA. Introgression of KIR2DS1 from archaic humans is also a possibility (35) . Our previous findings do indicate that KIR2DS1 and KIR3DS1 (both on tB) are selected against in SSA (14) . Studying disorders of pregnancy in an African setting is important and informative; the high rates of pre-eclampsia as well as other major disorders of pregnancy including obstructed labour and stillbirth and the greater genetic diversity of KIR in SSA mean unravelling the role of the complex KIR and HLA systems will provide valuable genetic information to predict women who are at risk of a range of pregnancy disorders.
Materials and Methods
Ethics statement. Approval to conduct the study was given by the Higher Degrees Research and Ethics Committee of Makerere University College of Health Sciences and the Uganda National Council for Science and Technology (UNCST). The participants gave written informed consent to participate in the study. Withdrawal from the study never jeopardized health care and this was provided free to all women.
Study design. This study was conducted at Mulago National Referral and Teaching Hospital, located in Kampala, which functions as a tertiary referral center for Uganda. Mulago hospital is the busiest maternity hospital in Sub-Saharan Africa, with over 30,000 deliveries a year. Genomic DNA was obtained from maternal blood from unrelated healthy women (n=484) or women with pre-eclampsia or eclampsia (n=254) between July 2009 and June 2011. Umbilical cord samples were obtained from the babies for genomic DNA isolation. Pre-eclampsia was defined as hypertension of 140/90 mmHg or more, on more than one occasion at least 4 hours apart plus proteinuria of +2 or more by dipstick, both at 20 weeks or more of gestation. Eclampsia was diagnosed when a patient with pre-eclampsia had generalized tonic-clonic convulsions. Controls were women with a normal first pregnancy delivering at term (≥38 weeks) who were normotensive with no proteinuria. Excluded from controls were patients taking long term medication and patients with other diseases including chronic hypertension and renal disease but excluding HIV. Women who had received a blood transfusion within the last 3 months were also excluded. Cases and controls were consecutively recruited from the same catchment area during the study period . Data was collected   545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586  587  588  589  590  591  592  593  594 Submission PDF at the time of clinical examination of the participants using an intervieweradministered questionnaire and additional information was obtained from medical charts.
DNA isolation and genotyping. Maternal genomic DNA was isolated from 5 ml of blood using the QIAamp DNA Maxi Blood Kit (Qiagen). Fetal DNA was isolated from umbilical cord samples after overnight incubation with Proteinase K (Roche), purification with a protein precipitation solution (Qiagen) followed by ethanol precipitation. Twelve maternal KIR genes were typed for presence or absence by PCR-SSP using two pairs of primers per gene or allele as described previously (8, 14, 36) . The KIR genes typed were 2DL1, 2DL2/3, 2DL5, 3DL1/S1, 2DP1, 2DS1, 2DS2, 2DS3, 2DS4 (including the deletion), and 2DS5. All the samples were typed for KIR2DL1 and KIR2DP1 copy number and 28 selected samples were further investigated for additional KIR (2DL4, 3DP1, 3DL2, 3DL3 ) so that all 14 KIR genes were included (37) . Individual genotypes were defined according to their combination of centromeric (cA and cB) and telomeric (tA and tB) KIR regions, based on previously described African KIR haplotypes (14, 15, 18) . We first discriminated KIR A from KIR B regions on the basis of the presence/absence of 2DS2, 2DL2/3, 2DP1, 2DL1, 3DL1/S1, 2DS1 and 2DS4. There are common cB regions in Africans (Figure 3 ) that were identified in individuals with a cB region using information from the presence/absence of individual KIR genes and the copy number of KIR2DL1 and KIR2DP1 (18) . Typically, cB01 and cB03 have 2DP1, 2DL1, 2DL5 and 2DS5 (or 2DS3) whereas cB02 lacks these genes. KIR2DS5 alleles were genotyped by pyrosequencing, targeting exons 5, 6, and 7 (15) . Then, by knowing which KIR2DS5 alleles are present in individuals homozygous for either centromeric A (cA) or telomeric A (tA) regions, we could assign each of the ten KIR2DS5 alleles to cB or tB (Figure 4 ). C1 and C2 were defined in maternal and fetal samples based on the primers and methods described previously (8, 36) . HLA-C low resolution allelic typing was performed using a PCR-SSP method consisting of 21 reaction wells adapted from (38) . Each well contained a final reaction volume of 10µl, consisting of 5x Green GoTaq Flexi Buffer (Promega), 0.2mM dNTPs (ThermoFisher), 1.25mM MgCl2 (Promega), 0.4U GoTaq DNA polymerase (Promega), 134nM 63/64 control primer (Eurogentec) and approximately 45ng DNA. PCR products were run on a 1% agarose gel and visualized using a UV and ethidium bromide.
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